(E)-1-(3-bromophenyl)-3-(3-methoxyphenyl)prop-2-en-1-one | 1381931-17-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-(3-bromophenyl)-3-(3-methoxyphenyl)prop-2-en-1-one
• CAS: 1381931-17-4
• 化学式: C₁₆H₁₃BrO₂
• 分子量: 317.182
• InChiKey: MZGZWEDIOIEKMI-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氟乙醇 、 (E)-1-(3-bromophenyl)-3-(3-methoxyphenyl)prop-2-en-1-one 在 bis(η3-allyl-μ-chloropalladium(II)) 、 caesium carbonate 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以84%的产率得到(E)-1-(3-(2-fluoroethoxy)phenyl)-3-(3-methoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  A general and efficient Pd-catalyzed rapid 2-fluoroethoxylation of bromo-chalcones

  摘要：

  An efficient unprecedented Pd-catalyzed rapid 2-fluoroethoxylation of bromo-chalcones has been unveiled. The oxygen nucleophiles (fluoroalcohols) experience the rapid C-O bond forming reaction for the first time, albeit the alcohols are known to be a weak nucleophile and have greater competing beta-hydride elimination in the transition-metal-catalyzed (especially Pd and Cu) C-O cross-coupling reaction. The higher fluoroalcohols have also been effectively coupled with bromo-chalcones with relatively lower rate. (C) 2016 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jfluchem.2016.04.013

文献信息

• [EN] COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF<br/>[FR] COMPOSITION POUR LE TRAITEMENT DU DIABÈTE ET DE MALADIES MÉTABOLIQUES, ET SON PROCÉDÉ DE PRÉPARATION
  申请人：UNIV KAOHSIUNG MEDICAL

  公开号：WO2013022951A1

  公开（公告）日：2013-02-14

  Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.

  揭示了一种用于治疗糖尿病和代谢综合征的茚素组合物。具体来说，在环A中与2-卤素结合的茚素化合物在体外抗糖尿病效应实验中显着降低了血糖水平。在体内动物模型中，主要的茚素化合物可以预防糖尿病的进展并控制血糖水平，体重增加方面没有显著差异。在为期七周的给药过程中，没有观察到肝脏或肾脏毒性。
• COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF
  申请人：WU YANG-CHANG

  公开号：US20130040996A1

  公开（公告）日：2013-02-14

  Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).

  本发明涉及一种用于预防和治疗动脉粥样硬化的组合物，其中包括查尔酮化合物。特别地，环A中与2-羟基结合，环B中与4'-甲氧基结合的查尔酮化合物具有多种治疗潜力，可作为PPARγ诱导剂、p44/42 MAPK抑制剂和细胞周期阻滞剂，且不对人体主动脉平滑肌细胞（HASMCs）显示毒性。此外，查尔酮化合物与PPARγ配体（罗格列酮）表现出协同作用，可抑制由氧化低密度脂蛋白（Ox-LDL）诱导的细胞增殖和cyclin D1、cyclin D3、白细胞介素-1β（IL-1β）和白细胞介素-6（IL-6）上调。
• COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF
  申请人：Wu Yang-Chang

  公开号：US20140350304A1

  公开（公告）日：2014-11-27

  Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.

  本发明公开了一种治疗糖尿病和代谢综合症的查尔酮组合物。特别是，环A中结合有2-卤素的查尔酮化合物在体外抗糖尿病实验中显著降低血糖水平。在体内动物模型中，主要的查尔酮化合物可以预防糖尿病的进展并控制血糖水平，体重增加也没有显著差异。在七周的给药过程中，没有观察到肝脏或肾脏毒性。
• US9085520B2
  申请人：——

  公开号：US9085520B2

  公开（公告）日：2015-07-21
• A general and efficient Pd-catalyzed rapid 2-fluoroethoxylation of bromo-chalcones
  作者：T.M. Rangarajan、Kavita Devi、Akhilesh K. Verma、Rishi Pal Singh、Raj Pal Singh

  DOI：10.1016/j.jfluchem.2016.04.013

  日期：2016.6

  An efficient unprecedented Pd-catalyzed rapid 2-fluoroethoxylation of bromo-chalcones has been unveiled. The oxygen nucleophiles (fluoroalcohols) experience the rapid C-O bond forming reaction for the first time, albeit the alcohols are known to be a weak nucleophile and have greater competing beta-hydride elimination in the transition-metal-catalyzed (especially Pd and Cu) C-O cross-coupling reaction. The higher fluoroalcohols have also been effectively coupled with bromo-chalcones with relatively lower rate. (C) 2016 Elsevier B.V. All rights reserved.